Key Highlights
- Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) reported Net Income of USD 16.5 million for the nine months ended September 30, 2026, against a net loss of USD 27.9 million a year earlier.
- The swing came from recognizing a previously deferred USD 35.0 million Immedica upfront payment as Revenue in June 2026, after Immedica chose not to pursue European approval of Iomab-B.
- The third-quarter net loss widened to USD 5.8 million from USD 5.1 million, with Research and Development expense of USD 4.7 million and no commercial revenue.
- Cash and cash equivalents were USD 28.7 million at September 30, 2026, down from USD 48.0 million at year end, while stockholders' Equity rose to USD 24.6 million.
A One-Time Revenue Release Drives the Nine-Month Profit
Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) filed its Quarterly Report on November 16, 2026, for the period ended September 30. The company develops targeted radiopharmaceuticals, including Iomab-B, Actimab-A, ATNM-400 and Iomab-ACT. Total revenue for the nine months was USD 35.0 million, against USD 0.09 million a year earlier. Nearly all of it was the Immedica upfront payment, which the company had booked as deferred license revenue since 2022. In June 2026 it concluded that Immedica's right to claim the money had expired. No income tax was recorded because the amount had already been included in federal taxable income, and the company keeps a full valuation allowance against deferred tax assets.
Third-Quarter Loss Widens on Higher Research Spending
Excluding that one-time item, operations still consumed cash. The third-quarter net loss of USD 5.8 million compared with USD 5.1 million a year earlier. Research and development expense, net of reimbursements, rose USD 0.5 million to USD 4.7 million on preclinical costs, clinical costs and headcount compensation. General and administrative expense eased to USD 1.4 million from USD 1.5 million. Interest income fell to USD 0.3 million from USD 0.6 million because the average cash balance was lower. For nine months, general and administrative expense dropped to USD 5.2 million from USD 13.1 million, mainly because 2025 included non-cash charges from a stock option cancellation.
Cash Position, Listing Plan and Share Count
Net cash used in operations was USD 18.1 million for the nine months, versus USD 19.3 million a year earlier, and USD 1.3 million went to Manufacturing improvements. Management expects existing resources to fund planned operations for more than 12 months, and no shares were sold in either period. The company received an NYSE American notice on May 27, 2026, over the stockholders' equity requirement. On August 14 it announced that regulators had accepted its compliance plan and set a plan period through November 27, 2027. As of November 13, 2026, 31,441,436 shares were outstanding and the company had 26 full-time employees.
Where Things Stand
The profit is real on paper but not operational. Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) booked USD 35.0 million of previously deferred revenue, which turned a USD 27.9 million nine-month loss into USD 16.5 million of net income. Without it, the company would have posted a loss, as the USD 5.8 million third-quarter result shows. Cash fell by about USD 19.3 million in the period, so spending, trial progress, manufacturing build-out and any further listing steps matter more than the headline profit. The next marker is the plan period running to November 27, 2027.


_11_20_2026_14_55_23_118425.jpg)



Please wait processing your request...